Updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC indicate selpercatinib or pralsetinib as a preferred treatment option for patients with RET fusion-positive NSCLC as a first-line or subsequent therapy (20). The gene discussed is RET; the disease is non-small cell lung carcinoma.